# A2 Biotherapeutics, Inc.

> A2 Biotherapeutics is a private clinical-stage biotechnology company developing Tmod logic-gated CAR T-cell therapies. Its activator-and-blocker design uses tumor-associated genetic loss to distinguish cancer cells from normal tissue. The company combines discovery, clinical development and in-house cell manufacturing, with investigational autologous and donor-derived programs for selected solid tumors.

- **Founded:** 2018
- **Headquarters:** Agoura Hills, United States
- **Founders:** Alexander Kamb (Founder and Chief Scientific Officer)
- **Products:** Tmod, A2B694, A2B543, A2B395, A2B530
- **Notable:** Launched publicly in November 2019 with a $57 million Series A., Dosed its first A2B530 patient in 2023 and first A2B694 patient in 2024., A2B543 received FDA Fast Track designation in April 2026.

## Products & services

- **Tmod** — Proprietary cell-engineering platform combining activating and blocking receptors; investigational, not a marketed treatment.
- **A2B694** — Autologous mesothelin-targeting CAR T-cell candidate with an HLA-A*02 blocker, studied in EVEREST-2.
- **A2B543** — Autologous mesothelin-targeting candidate with an inducible membrane-tethered IL-12 booster; EVEREST-2 Arm 2.
- **A2B395** — Donor-derived EGFR-targeting CAR T-cell candidate with an HLA-A*02 blocker; DENALI-1.
- **A2B530** — Earlier autologous CEA-targeting candidate studied in EVEREST-1; enrollment is closed.
- **BASECAMP-1** — Master prescreening study identifying patients with tumor HLA loss for interventional trials.

## Achievements

- Launched publicly in November 2019 with a $57 million Series A.
- Dosed its first A2B530 patient in 2023 and first A2B694 patient in 2024.
- A2B543 received FDA Fast Track designation in April 2026.
- Reported a centrally confirmed complete response in one NSCLC patient receiving A2B694, followed by an isolated CNS relapse.
- September 2026 DENALI-1 update reported a complete response in anal cancer and a partial response in head and neck cancer among nine efficacy-evaluable patients.

## Latest updates

- **2026-09** — DENALI-1 update: 10 treated, nine efficacy-evaluable; one CR, one PR, five stable disease, two progressive disease. Cell Coast presentation scheduled October 9-11.
- **2026-05** — EVEREST-2 update included 13 phase 1 patients and follow-up of a lung-cancer complete response, including an isolated CNS relapse.
- **2026-04** — FDA Fast Track designation granted to A2B543.
- **2026-02** — Announced first A2B543 patient dosed in EVEREST-2.
- **2026-01** — Announced FDA IND clearance for A2B543.

## Links

- Website: https://a2bio.com
- LinkedIn: https://www.linkedin.com/company/a2-biotherapeutics/

---

Profile page: https://yespress.io/a2-biotherapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-10-07